// App-Quantinova.ai

: EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma

Researchers

Presenter

  • Djamila Chemlal

Principal Investigators

  • Emmanuel Varlet

  • Amelie Machura

  • Guilhem Requirand

  • Nicolas Robert

  • Elina Alaterre

  • Laure Vincent

  • Charles Herbaux

  • Giacomo Cavalli

  • Angelique Bruyer

  • Hugues De Boussac

  • Jerome Moreaux

Medical Centers

  • Department of Hematology, Montpellier University Hospital, Montpellier, France

  • Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France

  • UFR Médecine, Université Montpellier, Montpellier, France

  • Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France

  • Institute of Human Genetics, UMR CNRS-UM, Montpellier, France

  • DiagTec, Montpellier, France

  • UMR CNRS-UM , Institute of Human Genetics, Montpellier, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Polycomb repressive complex 2

  • Enhancer of zeste homolog 2

  • Trimethylation of lysine 27 on histone H3

Drug/Treatment

  • daratumumab Intravenous

  • Isatuximab

  • Tazemetostat

  • Sandolase

  • EZH2

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved